Skip to main content



Biologic Persistence in Psoriatic Arthritis and Psoriasis

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

May 19, 2022

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. Such findings may be important in disorders like rheumatoid arthritis (RA)

Read Article
Malar,rash,SLE, Lupus

Rising Incidence of Systemic Lupus Erythematosus

May 17, 2022

Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.

SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.

They identified a total

Read Article

Acute Inflammatory Responses Needed to Resolve Chronic Pain

May 16, 2022

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Apr 21, 2022

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Both MAbs are neutralizing antibodies against SARS

Read Article

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article

ACR Fellow Training Subcommittee Report on Pandemic Experiences

Apr 11, 2022

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

Read Article

FDA Authorizes 2nd Booster for Older and Immunocompromised Individuals

Mar 29, 2022

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised

Read Article

Are Shoulder Conditions Incited by Vaccination?

Mar 21, 2022

A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle. 

Read Article

Environmental Pollutants Ups Autoimmune Disease Risk

Mar 16, 2022

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Previously environmental pollutants have been linked to an increased risk of

Read Article
RA, hands, MCP, deformity

Low Dose IL-2 Efficacy in Rheumatoid Arthritis

Mar 15, 2022

A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).

Low-dose interleukin-2 (Ld-IL2)

Read Article

Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients

Mar 04, 2022

JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (

Read Article
The new updated 2022 ACIP immunization schedule for adults has been published.
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2022
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Feb 11, 2022

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in

Read Article
ICYMI: The CDC's Advisory Committee on Immunization Practices recently recommended & approved 2 doses of the recombinant zoster vaccine for prevention of herpes zoster and complications in immunodeficient/immunosuppressed adults aged ≥19 years.
Dr. John Cush @RheumNow( View Tweet )
Jan 24, 2022
The CDC's Advisory Committee on Immunization Practices recently recommended & approved 2 doses of the recombinant zoster vaccine for prevention of herpes zoster and complications in immunodeficient/immunosuppressed adults aged ≥19 years.
Dr. John Cush @RheumNow( View Tweet )
Jan 21, 2022

Herpes Zoster Vaccination in Immunocompromised Adults

Jan 20, 2022

The CDC's Advisory Committee on Immunization Practices (ACIP) recently recommended and approved two doses of the recombinant zoster vaccine (RZV, AKA Shingrix) for prevention of herpes zoster and complications in immunodeficient or immunosuppressed adults aged ≥19 years.

Read Article

Referral Rules for At-Risk Inflammatory Arthritis

Jan 19, 2022

A prospective primary care study of patients at-risk for inflammatory arthritis (IA) showed that progression to IA was most likely in those with high anti-CCP antibody titers levels and involvement of the hands/feet/ IA. Interestingly, progression to IA was also seen in those who were

Read Article
COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today
Jan 18, 2022

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article

Hold Myophenolate or Not with COVID-19 Vaccination?

Jan 13, 2022

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody

Read Article

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
pill pillbox adherence

Comorbidities Drive Risk of Severe Outcomes with COVID-19

Jan 06, 2022

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

Read Article